University of Ilorin Teaching Hospital

University of Ilorin Teaching Hospital, Ilorin 241102, Kwara, Nigeria

Public Hospital, University or Academic Center

Serves Western Africa

The University of Ilorin Teaching Hospital (UITH) is a 2nd generation teaching hospital and public hospital in Ilorin, Kwara State, Nigeria. Built in 1980, UITH is a major public health center funded by the Federal Government of Nigeria. The hospital serves as a referral center for the whole of Kwara State, some contiguous communities of Oyo, Ondo, Osun, Niger, and Kogi States. Patients are often received from distant states of the federation such as Lagos State and the Federal Capital Territory.

Links to previous clinical trials:

https://clinicaltrials.gov/study/NCT03173729?lat=8.5374599&lng=4.6467767&locStr=University%20of%20Ilorin%20Teaching%20Hospital,%20University%20of%20Ilorin%20Teaching%20Hospital,%20Ilorin,%20Nigeria&distance=50&rank=9

https://clinicaltrials.gov/study/NCT03151629?lat=8.5374599&lng=4.6467767&locStr=University%20of%20Ilorin%20Teaching%20Hospital,%20University%20of%20Ilorin%20Teaching%20Hospital,%20Ilorin,%20Nigeria&distance=50&rank=10

https://clinicaltrials.gov/study/NCT01350856?lat=8.5374599&lng=4.6467767&locStr=University%20of%20Ilorin%20Teaching%20Hospital,%20University%20of%20Ilorin%20Teaching%20Hospital,%20Ilorin,%20Nigeria&distance=50&page=2&rank=12#contacts-and-locations

Site Capabilities

Clinical Trial Experience

Therapeutic area interests:

  • Cancer
  • Infectious disease

    • Institution has received grant(s) from:

  • National Funder(s)
  • International Funder(s)

    • Sponsors for previous clinical trials include:

  • Academic
  • Government
  • Industry
  • Investigator-initiated

    • Previous clinical trials conducted:

  • Behavioral
  • Diagnostic
  • Drug – biologic
  • Drug – small molecule
  • Epidemiological
  • Observational
  • Surgical
  • Vaccine

    • Study phase capabilities:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

    • Pediatric research capabilities:

  • Yes

    • Institution Regulatory/Research Ethics Committees

    Frequency of meetings: Monthly

    Application turnaround time (IRB/IEC): 3-4 weeks

    Average time from receipt of final protocol to review and approval of study by all relevant committees: 3-4 weeks

    Additional compliance:

  • IRB/IEC in compliance with IC E6(R2) in terms of composition, functions, and operations guidelines
  • Institution and/or local regulation mandates the distribution of study safety reports to IRB/IEC

    • Institution Staffing Resources

    Staff typeStaff available (y/n) and specialty experience
    Research coordinatorYes
    -Experience in Clinical Trials
    -Training in Human Subjects Protection (HSP)
    -Training in Good Clinical Practice (GCP)
    -Training in Good Clinical Laboratory Practice (GCLP)
    Research nurseYes
    -Experience in Clinical Trials
    -Training in Human Subjects Protection (HSP)
    -Training in Good Clinical Practice (GCP)
    -Training in Good Clinical Laboratory Practice (GCLP)
    Research data managerYes
    -Experience in Clinical Trials
    Quality assurance managerYes
    BiostatisticiansYes
    -Training in Good Clinical Practice (GCP)
    Database programmersYes
    EpidemiologistsYes
    -Training in Good Clinical Practice (GCP)
    PathologistsYes
    PharmacistsYes
    -Training in Good Clinical Practice (GCP)
    Behavioral ScientistsYes

    Institution Diagnostic Capabilities

  • Institution has personnel capable of performing diagnostic biopsies

    • Biopsies performed on-site:

  • Core needle biopsy
  • Endoscopic biopsy
  • Fine needle aspirate
  • Liquid biopsy
  • Sentinel lymph node biopsy
  • Skin biopsy
  • Surgical biopsy

    • Laboratory basics:

  • Institution has a laboratory on site
  • Institution sends diagnostic samples to external laboratory
  • Institution’s laboratory has been inspected or audited

    • Laboratory accreditations:

  • Good Laboratory Practices (GLP)

    • Tests performed on-site:

  • Complete blood count (CBC) with differential
  • Comprehensive metabolic-chemistry panel (CMP)
  • Routine urinalysis
  • Antibody tests
  • Antigen tests
  • Antimicrobial susceptibility and sensitivity
  • Bacterial smear and culture
  • Flow cytometry
  • Fluorescent in situ hybridization (FISH)
  • Fungal culture
  • Genetic testing
  • Histology
  • Immunohistochemistry (IHC)
  • Laboratory-developed tests (LDTs)
  • Microscopy
  • Ova and parasite (O&P) test
  • PCR and/or RT-PCR
  • Other nucleic acid amplification tests (NAATs)
  • Viral culture
  • Viral load

    • Imaging capabilities:

  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI)
  • Positron emission tomography (PET)
  • Nuclear imaging
  • Ultrasound
  • X-ray
  • Pediatric imaging

    • Institution Research Systems, Recordkeeping, and Data Management

  • Institution adheres to informed consent processes compliant with ICH E6(R2)
  • Institution follows ICH E6(R2) for collection and storage of source documentation for paper and/or electronic records
  • Institution stores patient records/source documents (paper/electronic) in a secured, limited access location during and after the trial
  • For source documents collected via electronic data capture, institution has a validated system and site procedures that follow ICH E6(R2) 5.5 guidelines
  • Institution has process in place for proper storage, archiving, and retrieval of essential study document per ICH 8.1
  • Institution study monitors have full access to source documents or certified copies of source documents (if electronic) if direct access can’t be obtained
  • Institution has a finance administration team
  • Institution undergoes routine financial audits

    • Institution Pharmacy

  • Pharmacy on site
  • Pharmacy has secure, limited access storage area with daily temperature monitoring and backup generator
  • Pharmacy has standard processes in place to ensure proper receipt, handling, and storage of investigational study drug/vaccine and comparators
  • Pharmacy has standard processes in place to ensure proper dispensing
  • Pharmacy has standard processes in place to ensure proper labeling that maintains the study blind
  • Pharmacy has standard processes in place to ensure proper drug/vaccine accountability, retrieval, and return or destruction of unused product
  • Institution has a secure, limited-access investigational drug/vaccine storage area with daily temperature monitoring
  • Institution’s pharmacy has a backup generator sufficient to run necessary equipment, refrigerators, freezers, etc.

    • Institution Equipment

  • Protocol for managing anaphylactic shock
  • Institution has a blood bank
  • Institution carries out blood transfusions for patients that need it
  • Functioning IV infusion pumps
  • Functioning basic life support equipment (crash cart)
  • Functioning electrocardiogram (EKG)

    • Availability of banked blood at institution:

  • Always available
  • Occasionally available
  • Rarely available

    • Institution performs the following routine blood screening tests on banked blood:

  • HIV
  • HBV
  • HCV
  • HPV
  • HTLVI
  • HTLVII
  • Syphilis

    • Additional information:

  • Institution’s equipment is calibrated and maintained per manufacturer’s guidelines
  • Institution’s equipment calibration and maintenance is documented
  • Institution’s laboratory has a secure, limited access biological specimen storage area with daily temperature monitoring
  • Institution’s laboratory has a backup power source, with alarm, sufficient to run necessary equipment, refrigerators, freezers, etc.
  • Institution maintains and uses a diagnostic imaging protocol manual
  • Laboratory maintains and uses a laboratory protocol manual
  • Laboratory maintains and uses a laboratory protocol manual

    • Program-Specific Capabilities

    Institution Cancer Treatment Capabilities and Equipment

  • Treats cancer patients
  • Performs surgical excisions
  • Administers chemotherapy
  • Uses radiation therapy

    • Radiotherapy machines on site:

  • Linear accelerator
  • Cobalt 60
  • Brachytherapy machine

    • Institution Infectious Disease Treatment Capabilities and Equipment

  • Treats infectious disease patients
  • Protocol for managing sepsis

    • Vaccines administered on site:

  • Polio
  • COVID
  • BCG
  • HPV
  • Hepatitis Vaccines

    • Infectious disease treatment services performed on site:

  • Antimicrobial/antibiotic drugs (small molecules or biologics; including antibacterial, antifungal, antiparasitic, antiviral medicines)
  • Immunotherapies
  • Supportive care/symptom management
  • Surgery
  • Viral load monitoring

    • Investigators at University of Ilorin Teaching Hospital

    Matthew Olumuyiwa Bojuwoye, MBBS, M.Sc.

    Senior Lecturer and Consultant Gastroenterologist, Department of Medicine

  • Cancer
  • Infectious Diseases

    • Overview

    Dr. Bojuwoye is a Senior Lecturer and Consultant Gastroenterologist in the Department of Medicine at University of Ilorin Teaching Hospital and University of Ilorin. In addition to his MBBS, he has a Master of Science in medical microbiology and parasitology, and expertise in medical oncology. His clinical trial interests include colorectal cancer (unique risk factors and tumor biology in Nigerians); liver cancer; Helicobacter pylori; and viral hepatitis.

    Formal Clinical Trial Training*

  • Formal GCP Training
  • Formal GCLP Training
  • Formal HSP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Samuel Adegboyega Olatoke, MBBS

    Consultant Surgeon, Surgical Oncologist, and Professor of General Surgery

  • Cancer

    • Overview

    Prof. Olatoke is a Consultant Surgeon, Surgical Oncologist, and Professor of General Surgery at University of Ilorin Teaching Hospital, with over 30 years of professional experience. His clinical trial interests include surgical treatment of breast and colorectal cancers. He was an investigator on a molecular and phenotypic profiling study of colorectal cancer patients in Nigeria.

    Formal Clinical Trial Training*

  • Formal GCP Training

    • Trial Phases

  • Phase III
  • Phase IV

    • Experience Conducting or Participating in Clinical Trials: Yes

    Previous Clinical Trials

    https://doi.org/10.1038/s41467-021-27106-w

    Ademola Popoola, MBBS

    Head, Department of Surgery; Professor of Urological Surgery; Honorary Consultant Urologist

  • Cancer

    • Overview

    Prof. Popoola is the Head of the Department of Surgery; Professor of Urological Surgery; and Honorary Consultant Urologist at University of Ilorin Teaching Hospital. He has expertise in surgical oncology. His clinical trial interests include observational and surgical studies for bladder, kidney, and prostate cancers. He has served as a principal investigator in several studies under the Prostate Cancer Transatlantic Consortium (CaPTC), such as the familial prostate cancer cohort study. He is currently the national principal investigator for the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN), and a vitamin D interventional study for prostate cancer.

    Formal Clinical Trial Training*

  • Formal GCP Training
  • Formal HSP Training

    • Experience Conducting or Participating in Clinical Trials: Yes

    Previous Clinical Trials

    https://clinicaltrials.gov/study/NCT03151629?lat=8.5374599&lng=4.6467767&locStr=University%20of%20Ilorin%20Teaching%20Hospital,%20University%20of%20Ilorin%20Teaching%20Hospital,%20Ilorin,%20Nigeria&distance=50&page=1&rank=10#collaborators-and-investigators

    *Definitions

    • HSP – Human Subjects Protection
    • GCP – Good Clinical Practice
    • GCLP – Good Clinical Laboratory Practice